RxDoctor Payments DataLook up a doctor →

Kevin Roberts, MD

Family Medicine · Little Rock, ARNPI 1336132372

Payments from drug & device makers

$2,530,289in general payments, 2019–2025

Across 1,011 payments — averaging $2502.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$1.3M
  • AbbVie$644K
  • AstraZeneca$252K
  • Novartis$182K
  • Pfizer$110K
  • Amgen$1K
  • plus $7K from 42 others
$97,311in research payments, 2019–2025

Across 14 payments — averaging $6950.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$97K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly43$1,333,387
AbbVie(2 entities)231$643,699
AstraZeneca73$251,650
Novartis19$182,496
Pfizer76$110,422
Amgen(2 entities)75$1,232
GSK79$1,141
Lilly USA, LLC95$1,109
Novo Nordisk37$540
Amarin Pharma, Inc.35$529
Astellas Pharma US Inc29$484
Merck35$478
Takeda Pharmaceuticals U.S.A., Inc.14$289
Biohaven Pharmaceuticals, Inc.17$263
Antares Pharma, Inc.13$249
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC15$241
Biohaven Pharmaceutical Holding Company Ltd.10$201
Corium, LLC9$201
Boehringer Ingelheim13$195
Bayer10$136
Bausch Health US, LLC6$125
Teva Pharmaceuticals USA, Inc.8$114
Johnson & Johnson7$103
Shire North American Group Inc7$93
Jazz Pharmaceuticals Inc.4$80
Sanofi Pasteur Inc.6$76
Exact Sciences4$76
Shield Therapeutics Inc4$73
Esperion Therapeutics, Inc.5$68
Nevro Corp.3$54
Halozyme Inc2$47
Tris Pharma Inc2$45
Genentech USA, Inc.3$40
Kowa Pharmaceuticals America, Inc.3$40
Eisai Inc.2$40
Collegium Pharmaceutical, Inc.2$34
Ironshore Pharmaceuticals Inc.2$32
Vertical Pharmaceuticals, LLC2$28
Sanofi-aventis U.S. LLC1$28
Nabriva Therapeutics, PLC2$27
Bristol Myers Squibb1$19
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$18
Dexcom, Inc.1$18
Currax Pharmaceuticals LLC1$16
Hologic Sales And Service, LLC1$16
Idorsia Pharmaceuticals US Inc1$14
Lundbeck LLC1$13
Nalpropion Pharmaceuticals LLC1$12

How this compares

$2,530,289 in reported general payments places this provider in the 95th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas →

Medicare billing

Part B allowed, 2024
$124,635
Medicare patients
478
Services billed
5,448

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family medicine in Little Rock

See the full list for Arkansas →

Where these figures come from

Is this you, or does something look wrong? →